cabergoline has been researched along with Adenoma in 107 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (1.87) | 18.7374 |
1990's | 11 (10.28) | 18.2507 |
2000's | 37 (34.58) | 29.6817 |
2010's | 39 (36.45) | 24.3611 |
2020's | 18 (16.82) | 2.80 |
Authors | Studies |
---|---|
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R | 1 |
Campana, C; Canevari, FR; Caputo, M; Castelletti, L; Ferone, D; Ferrero, A; Gaggero, G; Gatto, F; Lania, A; Lavezzi, E; Marzullo, P; Nista, F; Rossi, DC; Zona, G | 1 |
Cohen, D; Eshkoli, T; Fraenkel, M; Goldbart, A; Gorshtein, A; Greenman, Y; Shimon, I; Tsvetov, G; Yoel, U; Zaid, D | 1 |
Boguszewski, CL; Botelho, MS; Franzini, ÍA; Nunes-Nogueira, VDS | 1 |
Akirov, A; Ayalon-Dangur, I; Duskin-Bitan, H; Gorshtein, A; Robenshtok, E; Shimon, I; Tsvetov, G | 1 |
Miller, KK; Tritos, NA | 1 |
Farrant, MT; Gunn, AJ; Milsom, SR; O'Sullivan, SM; Ogilvie, CM | 1 |
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H | 1 |
Arvigo, M; Bruzzone, E; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, L; Lamberts, S; van der Pas, R; van Koetsveld, P | 1 |
Dekkers, OM; Fleseriu, M; Karavitaki, N | 1 |
Kawakami, K; Matsubayashi, K | 1 |
Biller, BMK; Tritos, NA | 1 |
Giraldi, EA; Ioachimescu, AG | 1 |
Abreu, C; Cadena-Obando, D; Cuevas-Ramos, D; Espinosa-de-Los-Monteros, AL; González-Virla, B; Ibarra-Salce, R; Mercado, M; Mercado-Cherem, A; Pérez-Reyes, SP; Portocarrero-Ortiz, LA; Sosa-Eroza, E; Talavera, JO; Vergara-López, A | 1 |
Barlier, A; Brue, T; Culler, MD; Cuny, T; Datta, R; Defilles, C; Dufour, H; Figarella-Branger, D; Graillon, T; Halem, HA; Landsman, T; Mougel, G; Saveanu, A; Zhang, S | 1 |
Duskin-Bitan, H; Gorshtein, A; Manisterski, Y; Masri, H; Rudman, Y; Shimon, I | 1 |
Cai, L; Li, Q; Lu, J; Su, Z; Wang, C; Wu, Z; Xu, J; Xu, Y | 1 |
Bronstein, MD; Greenman, Y | 1 |
Agostini, H; Arnoux, A; Brailly-Tabard, S; Chanson, P; Kuhn, E; Massart, C; Mavromati, M; Piketty, ML; Souberbielle, JC; Young, J | 1 |
Barkan, AL; Hollon, TC; Savastano, LE; Sullivan, SE | 1 |
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
Seow, CJ; Young, WF | 1 |
Croxson, MS; Holdaway, I; Kunasegaran, S; Murphy, R | 1 |
Cosio, C; Fracassi, F; Garatti, M; Grinwis, GCM; Kooistra, HS; Luccardini, L; Sartori, E | 1 |
Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS | 1 |
Akirov, A; Eizenberg, Y; Glaser, B; Greenman, Y; Mansiterski, Y; S'chigol, I; Shimon, I; Shraga-Slutzky, I | 1 |
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R | 1 |
Reincke, M; Theodoropoulou, M | 1 |
Batista, RL; Cescato, VAS; Cunha-Neto, MB; da Silva, GO; Herkenhoff, CGB; Medeiros, RSS; Musolino, NRC; Trarbach, EB | 1 |
Arosio, M; Ferrante, E; Giavoli, C; Indirli, R; Mantovani, G; Sala, E | 1 |
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W | 1 |
Asha, HS; Cherian, KE; Paul, TV; Rajan, R | 1 |
Abucham, J; Boguszewski, CL; Bronstein, MD; Correa-Silva, SR; Czepielewski, MA; Duarte, FG; Gadelha, MR; Huayllas, MKP; Jallad, RS; Kasuki, L; Musolino, NR; Naves, LA; Ribeiro-Oliveira Junior, A; Soares, BS; Vilar, L | 1 |
Abreu, A; Albarrán, AA; Carrasco, CA; Espinosa de los Monteros, AL; Gadelha, M; Mercado, M | 1 |
Aller, J; Alvarez-Escolá, C; Bernabeu, I; Biagetti, B; Blanco, C; Cámara, R; Castells, I; Fajardo, C; García, R; Gaztambide, S; Mora, M; Picó, A; Pozo, CD; Resmini, E; Salinas, I; Sesmilo, G; Soto, A; Torres, E; Villabona, C; Webb, SM | 1 |
Marek, J | 1 |
Cleemann, L; Holm, K; Jarløv, AE; Lewis, A | 1 |
Colli, LM; de Castro, M; Gadelha, MR; Gasparetto, EL; Kasuki, L; Marques, NV; Moraes, AB; Takiya, CM; Vieira Neto, L; Wildemberg, LE | 1 |
Bronstein, MD; Fleseriu, M; Greenman, Y; Jallad, RS; Shimon, I; Yedinak, CG | 1 |
Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M | 1 |
De Pue, A; Lutin, B; Paemeleire, K | 1 |
Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X | 1 |
Dhanjal, MK; Knight, M; Lambert, K; McCance, DR; Rees, K; Seed, PT; Williamson, C | 1 |
Barbieri, F; Culler, MD; Dong, J; Dufour, H; Feelders, RA; Florio, T; Gunz, G; Hofland, LJ; Jaquet, P; Moreau, JP; Saveanu, A; Spaziante, R; Stalla, GK; Taylor, JE; Theodoropoulou, M; van Koetsveld, PM; Zona, G | 1 |
Bolu, E; Kebapcilar, L; Kutlu, M; Sahin, M; Taslipinar, A; Uckaya, G | 1 |
Drake, WM; Metcalfe, KA; Moyes, VJ | 1 |
Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I | 1 |
Matsuno, A | 1 |
Ambrosio, MR; Buratto, M; Degli Uberti, EC; Filieri, C; Lapparelli, M; Minoia, M; Scanarini, M; Tagliati, F; Zatelli, MC | 1 |
Coiré, CI; Horvath, E; Kovacs, K; Rosso, D; Smyth, HS | 1 |
Benbassat, C; Grozinsky-Glasberg, S; Shimon, I; Tzvetov, G | 1 |
Burger, P; Menucci, M; Quiñones-Hinojosa, A; Salvatori, R | 1 |
Albuquerque, JL; Azevedo, MF; Casulari, LA; Faria, MS; Figueiredo, P; Montenegro, RM; Nascimento, GC; Naves, LA; Vilar, L | 1 |
Bianchi, A; Carrozza, C; D'Ercole, M; Della Pepa, GM; Doglietto, F | 1 |
Barbieri, F; Culler, MD; Ferone, D; Florio, T; Gatti, M; Gatto, F; Giusti, M; Hofland, LJ; Minuto, F; Ravetti, JL; Saveanu, A; Schulz, S; Wurth, R; Zona, G | 1 |
DeCubellis, J; Donnelly, T; Kiupel, M; Mayer, J; Sato, A | 1 |
Cottier, JP; François, P; Gilbert-Dussardier, B; Girard, JJ; Jan, M; Lecomte, P; Richard, S; Trouillas, J; Tudorancea, A | 1 |
Ahmed, A; Furqan, S; Islam, N | 1 |
Barahona Constanzo, MJ; del Pozo Picó, C | 1 |
Fukuoka, H; Iguchi, G; Inoshita, N; Nishizawa, H; Suda, K; Takahashi, M; Takahashi, Y; Yamada, S; Yamamoto, M | 1 |
Anand, KS; Dhikav, V | 1 |
Bianchi, A; De Marinis, L; Doglietto, F; Giampietro, A; Iacovazzo, D; Lauriola, L; Lucci-Cordisco, E; Lugli, F; Milardi, D | 1 |
Biesold, M; Guenzel, S; Lohmann, T; Paschke, R; Prothmann, S; Schober, R; Trantakis, C | 1 |
Akintoye, SO; Bianco, P; Booher, S; Chebli, C; Cherman, N; Collins, MT; Feuillan, P; Kushner, H; Leroith, D; Robey, PG; Wientroub, S | 1 |
Annunziato, L; Arvigo, M; Colao, A; De Caro, ML; de Herder, WW; Ferone, D; Hofland, LJ; Kros, JM; Lamberts, SW; Lombardi, G; Pivonello, R | 1 |
Díez, JJ; Iglesias, P; Macho, LP | 1 |
Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A | 1 |
Date, I; Hashimoto, K; Inagaki, K; Makino, H; Miyoshi, T; Ogura, T; Otsuka, F; Suzuki, J; Takeda, M | 1 |
Gomes, MC; Knoepfelmacher, M; Melo, ME; Mendonca, BB | 1 |
Rickels, MR; Snyder, PJ | 1 |
Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M | 1 |
Góth, MI; Iván, G; Nagy, GM; Oláh, M; Szigeti-Csúcs, N | 1 |
Boianov, M; Khristov, V; Vezenkova, L | 1 |
Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A | 1 |
Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH | 1 |
Culler, MD; Dufour, H; Guillen, S; Gunz, G; Jaquet, P; Saveanu, A | 1 |
de Herder, WW; Feelders, RA; Krenning, EP; Kwekkeboom, DJ; Reijs, AE; Tanghe, HL; van Aken, MO; van der Lely, AJ | 1 |
Georgieva, J; Nussbaum, G; Rochlitz, H; Steinhoff, M; Zouboulis, CC | 1 |
Enseñat, J; Mesa, J; Obiols, G; Ortega, A; Sahuquillo, J; Topcewski, T; Vilalta, J | 1 |
Cappabianca, P; Colao, A; Cozzi, R; Ghigo, E; Martino, E; Scanarini, M | 1 |
Tokhunts, KA | 1 |
Greenman, Y | 1 |
Ali, O; Banerjee, S; Kelly, DF; Lee, PD | 1 |
Adamo, V; Manno, M; Marchesan, E; Tomei, F | 1 |
Barlier, A; Brue, T; Jaquet, P; Saveanu, A | 1 |
Ambrosi, B; Angioni, AR; Baglioni, S; Barbieri, AM; Beck-Peccoz, P; Borretta, G; Brogioni, S; Cannavò, S; Colao, A; Filopanti, M; Fustini, MF; Gasco, V; Gasperi, M; Grottoli, S; Jaffrain-Rea, ML; Lania, A; Mantovani, G; Monte, PD; Peri, A; Pigliaru, F; Spada, A | 1 |
Ajossa, S; Depau, GF; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM | 1 |
Biller, BM; Cannistraro, KB; Davis, KR; Klibanski, A; Molitch, ME; Schoenfelder, JR; Simons, JA; Vance, ML | 1 |
Jeffreys, R; Leese, G; Vora, J | 1 |
Arosio, M; Biella, O; Faglia, G; Gambino, G; Muratori, M; Romano, C | 1 |
Bertagna, A; Camanni, F; Camanni, M; Cammarota, T; Ciccarelli, E; Cirillo, S; Gaia, D; Grottoli, S; Razzore, P | 1 |
Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J | 1 |
Attanasio, R; Barausse, M; Branca, V; Cozzi, R; Da Re, N; Dallabonzana, D; Gelli, D; Oppizzi, G; Orlandi, P | 1 |
Bartolone, L; Blandino, A; Cannavò, S; Galatioto, S; Spinella, S; Trimarchi, F | 1 |
Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J | 1 |
Colao, A; Di Salle, F; Faggiano, A; Filippella, M; Lombardi, G; Pivonello, R | 1 |
Cerbone, G; Colao, A; Di Sarno, A; Di Somma, C; Ferone, D; Lastoria, S; Lombardi, G; Lucci, R | 1 |
Andersen, M; Bjerre, P; Edal, A; Hagen, C; Høilund-Carlsen, PF; Pedersen, PH; Schrøder, HD | 1 |
Beckers, A; Bloch, B; Kalife, A; Petrossians, P; Ronci, N; Stevenaert, A; Tabarin, A; Valdés Socin, H | 1 |
Maschek, W; Pichler, R | 1 |
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A | 1 |
Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW | 1 |
Nippoldt, TB; Sheehan, MT | 1 |
Góth, M; Hubina, E; Kovács, L; Szabolcs, I | 1 |
Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F | 1 |
Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D | 1 |
Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE | 1 |
15 review(s) available for cabergoline and Adenoma
Article | Year |
---|---|
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2021 |
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.
Topics: Adenoma; Aged; Cabergoline; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pituitary Neoplasms; Prolactin; Retrospective Studies | 2022 |
Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.
Topics: Adenoma; Cabergoline; Humans; Pituitary Neoplasms | 2022 |
Diagnosis and Management of Pituitary Adenomas: A Review.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Child; Female; Human Growth Hormone; Humans; Hypopituitarism; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2023 |
Advances in the Medical Treatment of Cushing Disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Cabergoline; Endocrinology; Humans; Mifepristone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Treatment Outcome | 2020 |
The Role of Dopamine Agonists in Pituitary Adenomas.
Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Human Growth Hormone; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2020 |
Advances in the medical treatment of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin | 2019 |
Tumor-Directed Therapeutic Targets in Cushing Disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin | 2019 |
[Recent trends in the pathophysiology and treatment of pituitary adenomas].
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamic Hormones; Incidental Findings; Neurosurgical Procedures; Octreotide; Pituitary Neoplasms; Prolactinoma; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Temozolomide | 2009 |
New prospects for drug treatment in Cushing disease.
Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin | 2012 |
Double pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Comorbidity; Ergolines; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Treatment Outcome | 2013 |
Treatment of pituitary tumors: dopamine agonists.
Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Receptors, Dopamine | 2005 |
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Topics: Adenoma; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sex Characteristics | 2006 |
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Cell Proliferation; Dopamine; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Protein Multimerization; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured | 2008 |
[Novel pharmacologic therapies in acromegaly].
Topics: Acromegaly; Adenoma; Aminoquinolines; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Hormones; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Prolactin; Receptors, Somatotropin; Somatostatin | 2002 |
11 trial(s) available for cabergoline and Adenoma
Article | Year |
---|---|
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.
Topics: Adenoma; Antiparkinson Agents; Cabergoline; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Pituitary Neoplasms; Prognosis; Receptors, Dopamine D2; Survival Rate | 2019 |
Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Longitudinal Studies; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Treatment Outcome | 2019 |
Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Visual Acuity | 2001 |
[Suppression of hyperprolactinemia in pituitary microadenoma with cabergoline (Dostinex)].
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Tumor Burden | 2005 |
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Topics: Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine; Drug Screening Assays, Antitumor; Ergolines; Female; Human Growth Hormone; Humans; Ligands; Male; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Recombinant Fusion Proteins; RNA, Messenger; Somatostatin; Tumor Cells, Cultured | 2006 |
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome | 2007 |
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Topics: Acromegaly; Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin | 1997 |
Cabergoline in the treatment of acromegaly: a study in 64 patients.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prospective Studies | 1998 |
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin | 1998 |
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Topics: Adenoma; Adult; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Pituitary Neoplasms; Predictive Value of Tests; Prolactin; Prolactinoma; Radionuclide Imaging | 2000 |
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies | 2001 |
81 other study(ies) available for cabergoline and Adenoma
Article | Year |
---|---|
Resistant prolactinomas: a case series of 26 patients.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult | 2022 |
Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study.
Topics: Adenoma; Aged; Aged, 80 and over; Cabergoline; Humans; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
Topics: Abortion, Spontaneous; Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Female; Humans; Infertility; Lactation; Pituitary Neoplasms; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult | 2020 |
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult | 2020 |
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Animals; Anti-Inflammatory Agents; beta-Arrestin 1; beta-Arrestin 2; Cabergoline; Cell Line, Tumor; Dexamethasone; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Ketoconazole; Male; Mice; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms | 2020 |
Endocrinology in the time of COVID-19: Management of pituitary tumours.
Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Coronavirus Infections; COVID-19; Disease Management; Dopamine Agonists; Hormone Replacement Therapy; Human Growth Hormone; Humans; Neurosurgical Procedures; Octreotide; Pandemics; Peptides, Cyclic; Pituitary Apoplexy; Pituitary Neoplasms; Pneumonia, Viral; Practice Guidelines as Topic; Radiotherapy; Somatostatin; Telemedicine; Time Factors; Visual Field Tests | 2020 |
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database.
Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult | 2020 |
Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Topics: Acromegaly; Adenoma; Adult; Cabergoline; Combined Modality Therapy; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Mexico; Middle Aged; Neurosurgical Procedures; Postoperative Period; Prognosis; Registries; Retrospective Studies; Somatostatin; Treatment Outcome | 2020 |
Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
Topics: Adenoma; Cabergoline; Dopamine; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured | 2021 |
True hyperprolactinemia in men without visible pituitary adenoma.
Topics: Adenoma; Adult; Aged; Cabergoline; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult | 2021 |
Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas.
Topics: Adenoma; Animals; Cabergoline; Dopamine Agonists; Female; Humans; Mice; Mice, Nude; Pituitary Neoplasms; Quassins; Xenograft Model Antitumor Assays | 2021 |
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.
Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden | 2021 |
Classification of Patients With GH Disorders May Vary According to the IGF-I Assay.
Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Dwarfism, Pituitary; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Male; Middle Aged; Neurosurgical Procedures; Somatostatin; Young Adult | 2017 |
Korsakoff syndrome from retrochiasmatic suprasellar lesions: rapid reversal after relief of cerebral compression in 4 cases.
Topics: Adenoma; Adult; Amnesia; Cabergoline; Cerebellar Diseases; Craniopharyngioma; Dopamine Antagonists; Humans; Korsakoff Syndrome; Male; Mammillary Bodies; Mental Disorders; Middle Aged; Nerve Compression Syndromes; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2018 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
An Overlooked Cause of Hypokalemia.
Topics: 14-alpha Demethylase Inhibitors; Adenoma; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Hypokalemia; Ketoconazole; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms | 2017 |
An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Young Adult | 2017 |
Prolactinoma in a Dog.
Topics: Adenoma; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Fatal Outcome; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography Scanners, X-Ray Computed | 2017 |
The efficacy of medical treatment in patients with acromegaly in clinical practice.
Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden | 2018 |
IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactinoma | 2018 |
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk; Treatment Outcome; Young Adult | 2019 |
McCune Albright syndrome: an endocrine medley.
Topics: Adenoma; Bone Density Conservation Agents; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Female; Fibrous Dysplasia, Polyostotic; Humans; Hyperthyroidism; Leg; Musculoskeletal Pain; Pituitary Neoplasms; Rare Diseases; Young Adult; Zoledronic Acid | 2019 |
Brazilian multicenter study on pegvisomant treatment in acromegaly.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brazil; Cabergoline; Child; Drug Therapy, Combination; Female; Growth Hormone; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Predictive Value of Tests; Receptors, Somatostatin; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2019 |
The role of primary pharmacological therapy in acromegaly.
Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Male; Octreotide; Pituitary Neoplasms; Somatostatin; Young Adult | 2014 |
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Injections, Subcutaneous; Insulin-Like Growth Factor I; Lipodystrophy; Male; Middle Aged; Octreotide; Receptors, Somatotropin; Retrospective Studies; Spain; Treatment Failure; Treatment Outcome | 2014 |
[Contemporary options and perspectives in the treatment of acromegaly].
Topics: Acromegaly; Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Radiosurgery; Receptors, Somatotropin; Somatostatin | 2014 |
[Pituitary apoplexy in a young woman].
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Apoplexy; Pituitary Neoplasms | 2014 |
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Receptors, Dopamine D2; RNA, Messenger; Treatment Outcome | 2015 |
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Male; Middle Aged; Remission Induction; Somatostatin; Treatment Outcome; Young Adult | 2015 |
Prolactinomas: evolution after menopause.
Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2016 |
Chronic cluster headache and the pituitary gland.
Topics: Adenoma; Cabergoline; Central Nervous System Cysts; Cluster Headache; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Sumatriptan; Treatment Outcome; Verapamil | 2016 |
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome | 2016 |
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
Topics: Adenoma; Adult; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cesarean Section; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Incidence; Pituitary Neoplasms; Pre-Eclampsia; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Prolactinoma; Prospective Studies; Stillbirth; United Kingdom; Vision Disorders; Young Adult | 2017 |
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Cell Division; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Fibroblasts; Humans; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Sulpiride; Thymidine; Tritium; Tumor Cells, Cultured | 2008 |
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.
Topics: Acromegaly; Adenoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cyclophosphamide; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Lymphoma, Non-Hodgkin; Male; Neoplasms, Multiple Primary; Octreotide; Prednisone; Thyroid Neoplasms; Thyroidectomy; Thyroxine; Vincristine | 2009 |
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Topics: Acromegaly; Adenoma; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Pituitary Gland; Prospective Studies; Treatment Outcome | 2008 |
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull | 2009 |
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
Topics: Adenoma; Aged; Apoptosis; Cabergoline; Cell Line, Tumor; Cell Survival; Ergolines; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pituitary Neoplasms; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Somatostatin; Vascular Endothelial Growth Factor A | 2010 |
A double pituitary adenoma presenting as a prolactin-secreting tumor with partial response to medical therapy. Case report.
Topics: Adenoma; Adult; Antineoplastic Agents; Breast Neoplasms, Male; Cabergoline; Combined Modality Therapy; Ergolines; Gonadotrophs; Humans; Male; Microscopy, Electron, Transmission; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neurofibromatosis 1; Neurosurgical Procedures; Prolactinoma | 2010 |
Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Hemoglobins; Humans; Hypogonadism; Male; Middle Aged; Prolactin; Prolactinoma; Retrospective Studies; Testosterone | 2011 |
Effect of dopaminergic drug treatment on surgical findings in prolactinomas.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Child; Dopamine Agents; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult | 2011 |
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Time Factors; Young Adult | 2011 |
Two diagnostic pitfalls mimicking a prolactin-secreting microadenoma.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Female; Galactorrhea; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Menstruation Disturbances; Pituitary Neoplasms; Prolactin | 2010 |
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Topics: Adenoma; Adult; Cabergoline; Cell Proliferation; Dopamine; Dopamine Agonists; Drug Synergism; Ergolines; Gene Expression; Humans; Immunohistochemistry; Male; Octreotide; Pituitary Neoplasms; Protein Isoforms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Tumor Cells, Cultured | 2012 |
Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat.
Topics: Adenoma; Animals; Antineoplastic Agents; Cabergoline; Ergolines; Male; Pets; Pituitary Neoplasms; Rats; Rodent Diseases | 2011 |
Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Male; Mutation; Pituitary Neoplasms; Prolactin; Somatostatin; Treatment Outcome; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2012 |
Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings.
Topics: 14-alpha Demethylase Inhibitors; Adenoma; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Diagnosis, Differential; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Severity of Illness Index; Tomography, X-Ray Computed | 2012 |
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Octreotide; Pituitary Gland; Retrospective Studies; Somatostatin; Tumor Burden; Young Adult | 2013 |
Hyperprolactinemia: an unusual cause of erectile dysfunction.
Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Treatment Outcome | 2013 |
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
Topics: Adenoma; Antineoplastic Agents; Body Height; Cabergoline; DNA Mutational Analysis; Ergolines; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits, Gs; Human Growth Hormone; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms | 2002 |
Dopamine receptor expression and function in corticotroph pituitary tumors.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Radioligand Assay; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2004 |
Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy.
Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hydrocephalus; Male; Pituitary Neoplasms; Prolactinoma | 2004 |
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadine; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Pituitary Neoplasms | 2004 |
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
Topics: Adenoma; Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Receptors, Dopamine D2; Treatment Outcome | 2004 |
Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hypopituitarism; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Stroke | 2004 |
Cabergoline decreases somatotroph adenoma size: a case report.
Topics: Adenoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Pituitary Neoplasms; Treatment Outcome | 2004 |
The clinical characteristics of headache in patients with pituitary tumours.
Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors | 2005 |
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms | 2006 |
Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 2006 |
Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma.
Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Face; Hair; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Testosterone; Thyroxine | 2007 |
[Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases].
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Cavernous Sinus; Combined Modality Therapy; Cranial Irradiation; Diabetes Insipidus, Neurogenic; Dose Fractionation, Radiation; Endoscopy; Ergolines; Female; Follow-Up Studies; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pituitary Neoplasms; Postoperative Complications; Predictive Value of Tests; Prognosis; Prospective Studies; Radiography; Radiotherapy, Adjuvant; Somatostatin; Sphenoid Bone; Treatment Outcome | 2006 |
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.
Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Humans; Somatostatin | 2006 |
Dopaminergic treatment of nonfunctioning pituitary adenomas.
Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine Agents; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin | 2007 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitus, Type 2; Ergolines; Gigantism; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pituitary Neoplasms; Radiotherapy | 2007 |
An important new adaption of a specific drug?
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A | 2007 |
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
Topics: Adenoma; Adult; Alleles; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Pituitary Neoplasms; Polymorphism, Genetic; Prolactin; Receptors, Dopamine D2; Retrospective Studies | 2008 |
Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman.
Topics: Adenoma; Adult; Amenorrhea; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactin | 1994 |
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Topics: Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Gonads; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Visual Fields | 1996 |
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Male; Middle Aged; Pituitary Neoplasms | 1997 |
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin | 1997 |
Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Time Factors | 1999 |
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics | 1999 |
Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Nelson Syndrome; Pituitary Neoplasms; Remission Induction | 1999 |
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Prognosis; Thyrotropin | 2001 |
ACTH silent adenoma shrinking under cabergoline.
Topics: Adenoma; Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Autoradiography; Cabergoline; Ergolines; Humans; In Situ Hybridization; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; RNA, Messenger | 2001 |
Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline.
Topics: Adenoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Ergolines; Female; Humans; Peptides, Cyclic; Somatostatin; Thyrotropin; Time Factors | 2001 |
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields | 2001 |
Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.
Topics: Abdominal Pain; Acromegaly; Adenoma; Adult; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Bilirubin; Cabergoline; Chemical and Drug Induced Liver Injury; Cholangiopancreatography, Endoscopic Retrograde; Cholelithiasis; Cholesterol; Ergolines; Gram-Negative Bacterial Infections; Hepatectomy; Humans; Insulin-Like Growth Factor I; Liver; Liver Diseases; Male; Octreotide; Pituitary Neoplasms; Postoperative Complications; Sepsis; Surgical Wound Infection | 2000 |
New perspectives in medical management of hyperprolactinemia.
Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 1990 |
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin | 1989 |
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats | 1988 |